Medicenna Therapeutics Corp has seen a modest uptick this week, but the company continues to navigate a challenging financial landscape.
In the latest trading session, Medicenna Therapeutics Corp (MDNA.TO) closed at C$0.46, reflecting a 1.23% decline for the day but a 2.56% increase over the past week. Despite these fluctuations, the stock remains down significantly year-to-date, with a staggering 60% loss. This week’s performance comes amid no major company-specific news, but there are several relevant headlines worth noting.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeAdvertisement
Market cap
$42.46M
52W high
$1.97
52W low
$0.34
1W change
+2.56%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 700.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+700.0% Upside
Current Price
C$0.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
40.5%
Annualized
90-Day Vol
68.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.33
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.38 | C$0.33 – C$0.43 |
| 60 trading days | C$0.36 | C$0.29 – C$0.43 |
| 90 trading days | C$0.33 | C$0.26 – C$0.43 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: While Medicenna's stock has shown some resilience this week, the overall downward trend in 2023 raises concerns for potential investors. The recent public offering and ongoing clinical trials may provide some support, but the company's financial health remains a critical factor.
Medicenna's stock is currently trading at 8% of its 52-week range.
The stock's 52-week range of C$0.34 to C$1.97 highlights substantial volatility, with current pricing significantly below previous highs, reflecting investor caution.
Bull case
The recent public offering raised about CDN$4.44 million, which could help Medicenna advance its lead programs and potentially position the company for future growth.
Bear case
With a year-to-date decline of 60% and a profit margin of 0%, Medicenna faces significant challenges. Its high beta of 1.89 indicates potential volatility, which might deter risk-averse investors.
Recent Company Headlines
This week, Medicenna Therapeutics Corp finalized terms for its public offering, pricing units at $0.50 each, which includes one common share and one-half warrant. This offering was completed successfully, raising approximately CDN$4.44 million to support its lead programs. Additionally, the company is progressing with its clinical trials, including the NEO-CYT study in collaboration with Fondazione Melanoma Onlus, which aims to evaluate MDNA11 in combination with nivolumab for treating high-risk Stage III cutaneous melanoma.
Advertisement
Technical Picture
Currently, Medicenna's stock is trading at C$0.46, which is 8% of its 52-week range of C$0.34 to C$1.97. The stock's 50-day moving average stands at C$0.39, suggesting a recent uptrend of 17.9% compared to the current price, while the 200-day moving average is significantly higher at C$0.78, reflecting a decline of 41.1% from the current price level. The stock has a beta of 1.89, indicating greater volatility compared to the market. Recent trading volume of 125,923 shares is notably higher than the 20-day average volume of 37,249 shares, suggesting increased interest in the stock.
Insider Activity
There is no recent insider activity reported for Medicenna Therapeutics Corp, which may indicate a lack of significant changes in ownership or confidence from insiders at this time.
Price Action Summary
As of the latest trading session, Medicenna closed at C$0.46, reflecting a 1.23% decrease for the day. However, the stock has shown a slight recovery over the week with a 2.56% increase, though it remains down 60% year-to-date.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
